Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

Results 1 - 20 of 56 : 1 2 3 Next »

Recs

0
Member Avatar Herbstmd (51.28) Submitted: 6/27/2014 8:51:51 AM : Underperform Start Price: $1.67 AMRN Score: -6.40

Much inappropriate interference from the leftist FDA.

Recs

0
Member Avatar stemcells2011 (86.78) Submitted: 1/23/2014 12:44:34 PM : Outperform Start Price: $1.72 AMRN Score: -3.04

Pros: Approved omega-3 drug & $200m+ cash on hand. If FDA changes their stance, upside would be significant.

Cons: GSK owns Lovaza, the main competition. The FDA doesn't seem keen on expanding Vascepa's label to treat a much larger indication with a potential market share similar to the former. It could be an expensive uphill battle over the next 6 months. Investing here is going on a leap of faith with management.

Recs

0
Member Avatar PharmTeam (57.74) Submitted: 12/20/2013 2:26:15 PM : Underperform Start Price: $1.98 AMRN Score: +17.34

I was pretty negative on this company going into the FDA panel, and was pretty successful in giving the thumbs down. I still don't think the odds of FDA approval are good, and today's 25% run up is a pretty good opportunity to 'short' again. This is really a (virtual) bet that the FDA will require the long term REDUCE-IT trial results before considering approving Vascepa for moderate hypertriglyceridemia.

Recs

0
Member Avatar bottomfisherman (33.21) Submitted: 10/31/2013 4:07:55 PM : Underperform Start Price: $1.65 AMRN Score: +3.04

Soon to be found on the Pink Sheets in the near foreseeable future.

Recs

0
Member Avatar fatmoneyrz (95.73) Submitted: 10/30/2013 3:12:48 PM : Outperform Start Price: $2.36 AMRN Score: -36.35

This is probably going to zero, but I'll take a gamble on caps on the long side just for fun.

Recs

0
Member Avatar log81 (< 20) Submitted: 10/17/2013 11:59:22 PM : Underperform Start Price: $1.99 AMRN Score: +22.74

Ouch.

Recs

0
Member Avatar thefifth (< 20) Submitted: 10/15/2013 6:31:10 PM : Outperform Start Price: $2.07 AMRN Score: -27.80

current price is fearful vs. most likely outcome

Recs

0
Member Avatar Rilac (97.84) Submitted: 10/11/2013 4:49:00 PM : Outperform Start Price: $5.87 AMRN Score: -83.94

after perusing the brief documents for the adcom on the 16th, it seems as if the price movement for Amarin has been over exaggerated. i read nothing really abhorrent. nonetheless i took in a position before today's closing

Recs

0
Member Avatar ulanve (62.73) Submitted: 10/7/2013 12:10:43 AM : Outperform Start Price: $7.20 AMRN Score: -91.39

amrn

Recs

0
Member Avatar TerryHoodSr (46.55) Submitted: 7/31/2013 3:46:45 PM : Outperform Start Price: $2.03 AMRN Score: -26.12

potential

Recs

0
Member Avatar justin0820 (66.27) Submitted: 7/21/2013 10:02:20 PM : Outperform Start Price: $5.55 AMRN Score: -82.72

Sure, why not.

Recs

0
Member Avatar tftarpey (< 20) Submitted: 6/24/2013 2:13:29 PM : Outperform Start Price: $5.94 AMRN Score: -93.27

Everyone on the blogs hate it. A simple effective product that gets the job done. It works for high tri-gs and will do so for lower tri-gs. WAKE Up This is to simple for high tech Pharma.

Recs

1
Member Avatar chris293 (86.36) Submitted: 5/7/2013 2:50:43 AM : Underperform Start Price: $7.05 AMRN Score: +94.66

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

Recs

0
Member Avatar mchedester (74.89) Submitted: 4/2/2013 7:26:24 AM : Outperform Start Price: $7.39 AMRN Score: -100.03

Oversold.

Recs

0
Member Avatar azinsd (< 20) Submitted: 3/30/2013 10:57:54 AM : Outperform Start Price: $7.42 AMRN Score: -100.14

Oh this is one is interesting - large consensus putting this one in 20s but for an NCE qualification that has little bearing on its performance - all star team in place to take this to finish line (much higher stock price) whatever it is

Recs

0
Member Avatar nijinksi (< 20) Submitted: 1/27/2013 3:42:49 PM : Outperform Start Price: $8.40 AMRN Score: -108.13

no real competitors in this field

Recs

0
Member Avatar SmartEquity (39.02) Submitted: 1/21/2013 9:08:25 AM : Outperform Start Price: $8.63 AMRN Score: -110.39

The market is discounting the commercialization potential of its star drug and not accounitng for the excellent team behind this launch.

Recs

0
Member Avatar cp15 (< 20) Submitted: 12/20/2012 10:52:51 AM : Outperform Start Price: $8.27 AMRN Score: -112.97

This Biotech in the middle of some mistakes has a lot potential because discovered and owned one of best medicaments that will be thrilling for many people's cardiovascular problems.

Recs

0
Member Avatar Kebin008 (< 20) Submitted: 12/17/2012 11:35:53 PM : Outperform Start Price: $8.74 AMRN Score: -114.59

Vacepa is an extremely valuable asset Amarin has. I remain bullish on this stock given the CEO Joe Z's background with acquisitions. It is difficult to value the company given the uncertainty surrounding NCE status. Given the extended delay from the FDA, I believe that NCE will be granted in the end. The FDA may just simply be looking for a way to grant Amarin this designation. Furthermore, I believe that the acquisition talks will progress in a much more progressive manner once NCE status has been decided. At the current price, Amarin has great upside potential with limited downside risks.

Recs

0
Member Avatar zbyrnes (< 20) Submitted: 10/25/2012 8:39:55 AM : Outperform Start Price: $12.67 AMRN Score: -122.75

Major patents picked up for new cholesterol/triglyceride/heart drug. Looking at huge buyout offers from big pharmaceuticals, namely AstraZeneca in the $4-8 billion range. Share values set to double on buyout.

Results 1 - 20 of 56 : 1 2 3 Next »

Featured Broker Partners


Advertisement